Colleagues from our biologics research and development arm, MedImmune (formerly Cambridge Antibody Technology), have long been based in Cambridge. Currently about 500 people are based at Granta Park. MedImmune is known as a world-leader in protein engineering and biologics drug development. In 2014, an additional 400 AstraZeneca employees have begun working at interim Cambridge locations, while the planning and building of our new site progresses. In addition to Granta Park, our interim locations include facilities at Melbourn Science Park and the Cambridge Science Park.
Our move to Cambridge reflects its global importance as a centre for biopharmaceutical research and development. The city offers invaluable access to world-leading scientific expertise and provides excellent opportunities for collaboration with renowned academic research institutions, pre-eminent hospitals and cutting-edge biotech companies.
Our focus on science
The Cambridge site will become our largest centre for oncology research worldwide. Beyond cancer research, our R&D will focus on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system. The site will bring together our small molecule and biologics R&D, opening up opportunities to exploit the promise of small and large molecule combinations. Additionally, we will have medicinal chemistry, high-throughput screening and cellular and molecular biology, as well as clinical development and pre-clinical research capabilities located on the site.
As our largest oncology research centre, the new site will also include a purpose-designed rodent facility principally to support our early stage cancer research.